Caris Life Sciences to Present Six Oncology Studies Utilizing Proprietary Multimodal Data at the AACR Annual Meeting 2026 Accessibility StatementSkip Navigation About Caris Life Sciences Caris Life Sciences® (Caris) is a leading, patient-centric, next-generation AI TechBio company and precision medicine pioneer actively developing and commercializing innovative solutions to transform healthcare. Through comprehensive molecular profiling (Whole Genome, Whole Exome and Whole Transcriptome Sequencing), advance ...

"In precision oncology, treatment selection is not only about identifying what may work but also understanding factors that may affect how safely a patient can receive therapy," said Caris President David Spetzler, MS, PhD, MBA. "During Colorectal Cancer Awareness Month, it is important to recognize that DPYD testing can provide clinically meaningful information before treatment begins, helping clinicians make more informed decisions for patients who may be candidates for fluoropyrimidine-based therapy." As ...

Caris Life Sciences Inc. (NASDAQ:CAI) is one of the best NASDAQ stocks under $30 to buy. On March 16, Caris Life Sciences expanded its Caris AI Insights portfolio with a new AI signature designed to predict early platinum resistance in patients with high-grade serous ovarian cancer/HGSOC. This tool uses the company’s proprietary CodeAI platform to analyze Whole Exome Sequencing/WES, Whole Transcriptome Sequencing/WTS, and clinical data. The signature aims to provide clinicians with molecular foresight in ...

Core Insights - Caris Life Sciences has published a study demonstrating the effectiveness of its GPSai algorithm in accurately diagnosing lung cancer, specifically differentiating lung squamous cell carcinoma from metastases of other origins [1][2][3] Group 1: Study Findings - The study analyzed 3,958 lung cancer cases diagnosed as squamous cell carcinoma, revealing that 123 cases were misdiagnosed as metastases from other primary cancers [2] - The reclassification of these cases led to treatment recommendations for 88 patients (71.5%) to change to guideline-preferred first-line systemic therapies, potentially improving patient outcomes [3] - Based on CDC data, it is estimated that around 1,000 lung cancer cases in the U.S. each year may be misdiagnosed as lung squamous cell carcinoma [3] Group 2: Clinical Impact - Caris GPSai has corrected a total of 3,857 cancer diagnoses since January 2024, enhancing diagnostic confidence for clinicians and ensuring patients receive appropriate care [4] - The integration of AI-driven predictions with comprehensive molecular profiling provides an additional layer of insight, which is crucial for accurate treatment recommendations [4] Group 3: Product and Technology - The GPSai algorithm is included in the MI Cancer Seek and MI Tumor Seek products at no extra cost, with FDA approval received in November 2024 for MI Cancer Seek [5] - Caris Life Sciences utilizes advanced AI and machine learning technologies alongside comprehensive molecular profiling to develop innovative diagnostic solutions for cancer [6]

Core Insights - Caris Life Sciences has launched a proprietary Caris AI Insights signature for pancreatic cancer, aimed at guiding first-line therapy selection and treatment de-escalation [1] - The Caris Molecular Tumor Board Report provides tumor profiling without additional tissue sampling, enhancing precision oncology through multimodal real-world datasets [1] - The new AI Insights utilize Whole Exome Sequencing (WES) and Whole Transcriptome Sequencing (WTS) to offer actionable insights for clinicians, particularly for pancreatic ductal adenocarcinoma (PDAC) [1] Company Developments - Caris Life Sciences integrates over 550,000 patient datasets to develop next-generation multimodal models for biomarker discovery and personalized cancer treatments [1] - The PDAC signature categorizes patients into standard or high risk and recommends treatment options based on molecular patterns, addressing the lack of actionable biomarker guidance in current therapies [1] - The company received FDA approval in November 2024 for MI Cancer Seek, the first tissue-based assay combining WES and WTS with FDA-approved companion diagnostic indications [1] Future Outlook - A future publication is anticipated to reveal how Caris AI Insights can identify patients suitable for treatment de-escalation and those who may benefit from more intensive therapies [1]

Financial Performance - The company incurred net losses of $68.1 million and $281.9 million for the years ended December 31, 2025 and 2024, respectively, with an accumulated deficit of $2.5 billion as of December 31, 2025[202]. - The company has incurred substantial indebtedness and may not generate sufficient cash flow to meet its debt service requirements[203]. - The company anticipates incurring significant expenses for R&D and commercialization efforts, which may lead to operating losses in the short term[205]. - The company has $796.3 million in cash and cash equivalents and $2.3 million in short-term marketable securities as of December 31, 2025[266]. - The company may need to raise additional capital to expand its business, meet obligations, pursue acquisitions, or fund new solutions[265]. Revenue Generation - The company's revenue is primarily generated from the adoption and use of its tissue-based profiling solution, with future success dependent on the market acceptance of solutions like MI Cancer Seek, Caris Assure, and Caris Detect[199][210]. - MI Profile accounted for 84.4% of the company's revenue for the year ended December 31, 2025[217]. - Revenue is significantly influenced by a limited number of third-party payers, and any changes in their reimbursement rates could adversely affect financial performance[231]. - The unpredictability of the reimbursement landscape complicates revenue recognition and could lead to significant fluctuations in quarterly and annual results[230]. - The company must achieve adequate coverage and reimbursement from third-party payers to ensure commercial success and revenue growth[236]. Regulatory Compliance - The company must navigate complex regulatory environments and compliance requirements, which could impact its business operations and financial results[203]. - The company is subject to investigations regarding compliance with Medicare's date of service rule, which could lead to significant penalties and affect financial results[258]. - The company is subject to stringent U.S. and foreign privacy and data security laws, which could result in significant liability and penalties for non-compliance[318]. - The company may incur substantial costs and face reputational harm if it fails to comply with evolving privacy and data security laws[331]. - Compliance with healthcare laws and regulations is critical, as failure to do so could result in substantial penalties and adversely affect the company's financial condition[313]. Product Development and Innovation - The company plans to enhance its solutions and reduce costs, but success in these areas is uncertain and may require regulatory approval[214]. - The company is expanding R&D efforts to develop new solutions, including Caris Detect for early detection and Caris ChromoSeq for hematological cancers, but successful commercialization requires extensive clinical validation[296]. - The validation and clinical trial process is lengthy and expensive, with uncertain outcomes that could delay product development and marketing authorization[306]. - The marketing authorization processes for new solutions are lengthy and unpredictable, with potential delays in obtaining necessary approvals from the FDA[367]. - The company faces risks related to maintaining relationships with biopharma partners, which are crucial for developing drug therapeutics and could impact financial performance if not sustained[300]. Market Competition - The precision medicine industry is highly competitive, with rapid technological changes and the need for continuous innovation to maintain market relevance[200]. - The precision oncology industry is highly competitive, with numerous companies offering similar services, potentially leading to significant price reductions and reduced market share for the company[277]. - The company faces significant challenges in maintaining and expanding market acceptance of its solutions, which are costly and time-consuming[221]. - Delays in clinical trials could allow competitors to bring products to market sooner, potentially harming the company's revenue generation capabilities[312]. Operational Risks - The company has faced significant operational and technological risks, which could adversely affect the performance and reliability of its solutions[212]. - The company relies on a limited number of third-party suppliers, including Illumina as the sole supplier for NGS instruments, which poses risks to its operations[262]. - The company may experience operational disruptions if its facilities or those of third-party collaborators are damaged or become inoperable[268]. - The company relies on third-party services for sample collection, processing, and storage, which if disrupted, could harm its business operations and reputation[304]. Legal and Ethical Considerations - Ethical, legal, and social concerns regarding genomic testing may limit market acceptance and demand for the company's solutions[373]. - The company is subject to ongoing federal, state, and local regulations regarding the handling and disposal of medical and hazardous materials, which may lead to unpredictable compliance costs[351]. - The company may face penalties for violations of state and foreign registration or licensing requirements for medical devices, potentially leading to denial or revocation of licenses[388]. - Employee use of generative AI tools may expose the company to intellectual property and privacy risks, potentially compromising confidential information[349]. Future Outlook - The company faces uncertainty regarding the regulatory requirements for its early detection and MRD tracking assays, as the FDA has never granted marketing authorization for such tests[340]. - The company is in the early stages of data licensing efforts, which may not develop into a sustainable business model, posing risks to financial stability[297]. - The company faces challenges in attracting and retaining qualified personnel, which is critical for its R&D and operational success[286]. - The company’s future capital requirements depend on various factors, including revenue growth and costs related to scaling operations[270].

Core Insights - Caris Life Sciences Inc. reported better-than-expected fourth-quarter earnings, with earnings of 28 cents compared to a consensus loss of 3 cents, and sales increased by 125% year over year to $292.89 million, surpassing the consensus of $208.63 million [1] Group 1: Financial Performance - The company achieved fourth-quarter earnings of 28 cents, significantly exceeding the expected loss of 3 cents [1] - Sales for the quarter rose 125% year over year to $292.89 million, beating the consensus estimate of $208.63 million [1] Group 2: Future Growth Prospects - The demand for Caris Life Sciences' platform is accelerating, contributing to strong growth in volume and revenue, with plans to launch the Caris Detect solution in the first half of 2026, which is seen as a significant growth opportunity [2] - The company reported advancements in its multi-cancer early detection test, Caris Detect, which utilizes Whole Genome Sequencing to improve early cancer detection capabilities [3] Group 3: Market Reaction and Analyst Ratings - Following the earnings announcement, Caris Life Sciences shares increased by 14.1% to $21.95 in pre-market trading [3] - Analysts have adjusted their price targets for Caris Life Sciences, with BTIG maintaining a Buy rating and lowering the target from $45 to $38, Baird maintaining an Outperform rating and raising the target from $26 to $28, and Evercore ISI Group maintaining an Outperform rating and lowering the target from $38 to $34 [4]

Caris Life Sciences Inc. (NASDAQ:CAI) shares are up during Friday’s premarket session following better-than-expected fourth-quarter earnings and a significant interim readout from the company’s Achieve 1 study.Sales More Than DoubledCaris Life Sciences on Thursday reported fourth-quarter earnings of 28 cents compared to the consensus loss of 3 cents.Sales for the quarter jumped 125% year over year to $292.89 million, beating the consensus of $208.63 million.The increase was driven primarily by a 199% growth ...

Core Insights - Premarket trading is showing notable activity with significant price movements indicating potential investment opportunities before the market opens [1] Premarket Gainers - Neurogene Inc. (NGNE) is up 34% at $26.42 [3] - Cardio Diagnostics Holdings, Inc. (CDIO) is up 20% at $6.29 [3] - Applied Optoelectronics, Inc. (AAOI) is up 19% at $64.00 [3] - Caris Life Sciences, Inc. (CAI) is up 19% at $22.93 [3] - Block, Inc. (XYZ) is up 18% at $64.59 [3] - MARA Holdings, Inc. (MARA) is up 16% at $9.84 [3] - NCR Atleos Corporation (NATL) is up 14% at $48.13 [3] - Birchtech Corp. (BCHT) is up 12% at $2.70 [3] - The RealReal, Inc. (REAL) is up 11% at $13.80 [3] - Candel Therapeutics, Inc. (CADL) is up 10% at $5.68 [3] Premarket Losers - Duolingo, Inc. (DUOL) is down 24% at $88.30 [4] - Xponential Fitness, Inc. (XPOF) is down 23% at $6.16 [4] - Emergent BioSolutions Inc. (EBS) is down 22% at $8.58 [4] - Flutter Entertainment plc (FLUT) is down 14% at $105.85 [4] - Ginkgo Bioworks Holdings, Inc. (DNA) is down 14% at $8.27 [4] - Willdan Group, Inc. (WLDN) is down 12% at $104.63 [4] - Duos Technologies Group, Inc. (DUOT) is down 12% at $7.67 [4] - CoreWeave, Inc. (CRWV) is down 11% at $85.96 [4] - Zscaler, Inc. (ZS) is down 9% at $152.22 [4] - Progyny, Inc. (PGNY) is down 8% at $20.40 [4]

​Caris Life Sciences, Inc. (NASDAQ:CAI) is one of the Best All-Time Low Stocks to Invest In Now. On February 24, Caris Life Sciences, Inc. (NASDAQ:CAI) announced that it is adding a new AI-powered “breast cancer signature” to its Caris Molecular Tumor Board Report. The report is a research tool that doctors and researchers use for additional tumor biology resources and can be ordered with the company’s MI Cancer Seek. ​Management noted that the report will now include a “Caris AI Insights” section with s ...